Menu Search
Equities

Angle PLC

AGL:LSE

Angle PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)9.75
  • Today's Change0.00 / 0.00%
  • Shares traded3.80m
  • 1 Year change-3.31%
  • Beta1.0080
Data delayed at least 20 minutes, as of Nov 12 2024 16:29 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Angle PLC grew revenues 109.99% from 1.04m to 2.19m while net income improved from a loss of 21.69m to a smaller loss of 20.13m.
Gross margin69.07%
Net profit margin-890.91%
Operating margin-959.88%
Return on assets-49.30%
Return on equity-63.75%
Return on investment-55.77%
More ▼

Cash flow in GBPView more

In 2023, cash reserves at Angle PLC fell by 15.68m. Cash Flow from Investing was negative at 203.00k, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 14.46m for operations while cash used for financing totalled 1.13m.
Cash flow per share-0.0598
Price/Cash flow per share--
Book value per share0.076
Tangible book value per share0.0677
More ▼

Balance sheet in GBPView more

Angle PLC appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.52% of the market capitalization can be attributed to its 16.22m and debt could be paid in full if management chose.
Current ratio5.19
Quick ratio4.80
Total debt/total equity0.1722
Total debt/total capital0.1469
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.